103 results
8-K
EX-1.1
RVNC
Revance Therapeutics Inc
5 Mar 24
Other Events
5:08pm
been no material adverse change in the capital stock, short-term indebtedness, long-term indebtedness, net current assets or net assets … information is given in the Pricing Prospectus there shall not have been any change in the capital stock or long term debt of the Company or any of its
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
. citizens or long-term residents, “controlled foreign corporations,” “passive foreign investment companies,” corporations that accumulate earnings
424B5
RVNC
Revance Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
6:39am
mark their securities positions to market for U.S. tax purposes, certain former U.S. citizens or long-term residents, “controlled foreign
8-K
EX-10.1
rf5hnjk2ckw7vuiic
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
8-K
EX-99.2
pqxu0s6nvl
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
zltefdf1gg8426sr dj
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-1.1
mb1nro h2e8
13 Sep 22
Other Events
9:55pm
424B5
h54wh7ghe6ipjvtmj1
13 Sep 22
Prospectus supplement for primary offering
9:13pm
424B5
8pko8kram 78zq
12 Sep 22
Prospectus supplement for primary offering
4:09pm